Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Previous studies have highlighted the clinical and biologic heterogeneity of acute myeloid leukemia (AML).1?4 However, a relatively small number of cytogenetic and molecular lesions have sufficient relevance to influence clinical practice.5 The prognostic relevance of cytogenetic abnormalities has led to the widespread adoption of risk stratification, with patients divided into three cytogenetically defined risk groups with significant differences in overall survival.6 More recently, FLT3, NPM1, and CEBPA mutational analysis was shown to improve risk stratification for patients who do not have karyotypic abnormalities.7 Although progress has been made in defining prognostic markers for AML, a substantial percentage of patients . . .